The data, which included 23 people, have not yet been peer-reviewed or published. During a company earnings call on Wednesday morning, Dr. Mikael Dolsten, who leads worldwide research, development and medical for Pfizer, called the new data on a third dose of vaccine “encouraging.” “Receiving a third dose more than six months after vaccination, when protection may be beginning to wane, was estimated to potentially boost the neutralizing antibody titers in participants in this study to up to 100 times higher post-dose three compared to pre-dose three,” Dolsten said in prepared remarks. “These preliminary data are very encouraging as Delta continues to spread.”
The data also show that antibody levels are much higher against the original coronavirus variant and the Beta variant, first identified in South Africa, after a third dose.
Read more of this story at Slashdot.